1. Inicio
  2. Universitat de Barcelona
  3. Economia
  4. Ver ítem

A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Autor/a

Darbà, Josep

Ramírez, Gabriela

García-Rivero, Juan L.

Mayoralas, Sagrario

Pascual, José Francisco

Roger, Albert

Vargas, Diego

Bijedic, Adi

Fecha de publicación

2017-03-02T15:37:24Z

2017-03-02T15:37:24Z

2016-09

2017-03-02T15:37:24Z

Compartir

Resumen

To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...

Tipo de documento

Artículo

Versión publicada

Lengua

Inglés

Materias y palabras clave

Administració de medicaments; Asma; Malalties pulmonars obstructives cròniques; Tractament tèrmic; Economia de la salut; Administration of drugs; Asthma; Chronic obstructive pulmonary diseases; Heat treatment; Medical economics

Publicado por

Dove Medical Press

Documentos relacionados

Reproducció del document publicat a: https://doi.org/10.2147/CEOR.S111453

Clinicoeconomics and Outcomes Research, 2016, vol. 8 , p. 435-444

https://doi.org/10.2147/CEOR.S111453

Citación recomendada

Esta citación se ha generado automáticamente.

Exportar

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Derechos

cc-by-nc (c) Darbà, Josep et al., 2016

http://creativecommons.org/licenses/by-nc/3.0/es

Este ítem aparece en la(s) siguiente(s) colección(ones)

Economia [1047]

ISGlobal - Institut de Salut Global de Barcelona [61457]